Vancouver, British Columbia–(Newsfile Corp. – December 21, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“ Lobe” or the “Company“) is pleased to announce its patent-pending therapeutic regimen that has been designed for treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder, and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder has been published by the World…


Previous articleMindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder
Next articleMydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments